MIRAMAR, Fla., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced a merger transaction with a public company that is DTC eligible and current with its SEC filings to serve as a vehicle for the quotation of the common stock of its subsidiary NuGenerex Immuno-Oncology (NGIO) as an independent, publicly traded company. Generex is in the process of finalizing its annual report on Form 10-K, which will be filed in the coming days. The Form 10-K will include the audited financial statements for the legal documentation and Super Form 8-K filing for the merger of NGIO with the public vehicle. We expect that NuGenerex Immuno-Oncology will be quoted on a public exchange by the end of November, and the 1:4 shareholder dividend that was paid to Generex shareholders in February 2019 will be converted into public shares shortly thereafter.
Generex has positioned its wholly-owned cancer subsidiary NuGenerex Immuno-Oncology to be merged with the public company, thereby completing the company’s go-public strategy to realize the value of the Ii-Key technology and AE37 immunotherapeutic vaccine program. NGIO is currently enrolling a Phase II trial to establish the recommended biologic dose for AE37 Peptide Vaccine in combination with Keytruda® (Pembrolizumab) that will enhance the tumor-specific immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer (NSABP FB-14); the trial is currently screening and enrolling patients at multiple clinical research sites.
Joseph Moscato, Generex President & Chief Executive Officer stated, “Generex has been a leader in immunotherapy for nearly 20 years, with a wealth of clinical experience developing li-Key Hybrid immunotherapy vaccines that activate the CD4 and CD8 T-Cell immune response to attack tumors. We have completed one of the largest cancer immunotherapy trials ever with a 300-patient trial evaluating our HER-2/neu vaccine AE37 for the prevention of breast cancer recurrence. The results of that trial have led to a clinical trial in triple negative breast cancer combining AE37 with Merck’s PD-1 inhibitor Keytruda® for the treatment of triple negative breast cancer. By merging NuGenerex Immuno-Oncology with the public vehicle, we are unlocking the value of our multimillion-dollar investment in the li-Key technology and the development of AE37 and other immunotherapeutic peptide vaccine products.”
“Further, we have plans to expand the clinical development of AE37 in combination with the FDA approved checkpoint inhibitors for the treatment of several cancers that express HER-2/neu including prostate, bladder, urothelial, and renal cancers. We also plan to reactivate our melanoma program with li-Key hybrids that target the melanoma tumor biomarkers, GP100 and TYR.”
“With the merger with this public company, we will not only have the vehicle for the NGIO listing, but we will also have a platform to incorporate additional companies, technologies, and immunotherapy products to augment the li-Key technology and advance our efforts in the field of cancer immunotherapy. I am happy that our GNBT shareholders will have the opportunity to realize the benefits of the NGIO stock dividend we paid at the beginning of the year and, as always, we will strive to continuously build value for our shareholders in Generex and now in NuGenerex Immuno-Oncology.”
About Generex Biotechnology Corp.
